Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological characteristics and responsiveness to systemic therapy. From the clinical standpoint, data suggest that ILC derives a disti...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2016-07, Vol.8 (4), p.261-266
Main Authors: Barroso-Sousa, Romualdo, Metzger-Filho, Otto
Format: Article
Language:English
Subjects:
Breast cancer
Clinical trials
Immunotherapy
Invasiveness
Monoclonal antibodies
Reviews
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological characteristics and responsiveness to systemic therapy. From the clinical standpoint, data suggest that ILC derives a distinct benefit from systemic therapy compared to IDC. In addition, comprehensive molecular analyses have been reported for ILCs, confirming that these tumors have specific genomic profiles compared to IDC. Despite these differences, clinical trials and practical clinical guidelines tend to treat BC as a single entity. Here we discuss these clinical and molecular data and their therapeutic implications.
ISSN:1758-8340
1758-8359
1758-8359
DOI:10.1177/1758834016644156